Is an SGLT2 inhibitor right for your patient with type 2 diabetes?

被引：0
作者：
Lisenby, Katelin M. [1 ]
Meyer, Allison [1 ]
Slater, Nicole A. [1 ]
机构：
[1] Auburn Univ, Harrison Sch Pharm, Dept Pharm Practice, Tuscaloosa, AL USA
来源：
JOURNAL OF FAMILY PRACTICE | 2016年 / 65卷 / 09期
关键词：
INADEQUATE GLYCEMIC CONTROL; METFORMIN PLUS SULFONYLUREA; LONG-TERM EFFICACY; ADD-ON THERAPY; DOUBLE-BLIND; BACKGROUND METFORMIN; SAFETY; EMPAGLIFLOZIN; PLACEBO; CANAGLIFLOZIN;
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
引用
收藏
页码：587 / 593
页数：7
相关论文
共 50 条
[41]   Marked Hypertriglyceridemia in a Patient with type 2 Diabetes Receiving SGLT2 Inhibitors [J].
Senoo, Mayumi ;
Tone, Atsuhito ;
Imai, Yusuke ;
Watanabe, Satoko ;
Kaneto, Mitsuhiro ;
Shimomura, Yasuyuki ;
Teshigawara, Sanae ;
Nakatou, Tatsuaki .
ACTA MEDICA OKAYAMA, 2021, 75 (01) :103-107
[42]   Response evaluation of SGLT2 inhibitor therapy in patients with type 2 diabetes mellitus using 18F-FDG PET/MRI [J].
Rasul, Sazan ;
Geist, Barbara Katharina ;
Brath, Helmut ;
Baltzer, Pascal ;
Sundar, Lalith Kumar Shiyam ;
Pichler, Verena ;
Mitterhauser, Markus ;
Kautzky-Willer, Alexandra ;
Hacker, Marcus .
BMJ OPEN DIABETES RESEARCH & CARE, 2020, 8 (01)
[43]   Efficacy and safety profile of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease [J].
Scheen, Andre J. .
EXPERT OPINION ON DRUG SAFETY, 2020, 19 (03) :243-256
[44]   The SGLT2 Inhibitor Dapagliflozin Increases the Oxidation of Ingested Fatty Acids to Ketones in Type 2 Diabetes [J].
Herring, Roselle A. ;
Shojaee-Moradie, Fariba ;
Stevenage, Mary ;
Parsons, Iain ;
Jackson, Nicola ;
Mendis, Jeewaka ;
Middleton, Benita ;
Umpleby, A. Margot ;
Fielding, Barbara A. ;
Davies, Melanie ;
Russell-Jones, David L. .
DIABETES CARE, 2022, 45 (06) :1408-1415
[45]   Bexagliflozin: a comprehensive review of a recently approved SGLT2 inhibitor for the treatment of type 2 diabetes mellitus [J].
Bassett, Ryan L. ;
Gallo, Giovanni ;
Le, Kim-Phuong N. ;
Volino, Lucio R. .
MEDICINAL CHEMISTRY RESEARCH, 2024, 33 (08) :1354-1367
[46]   A comparison of effects of DPP-4 inhibitor and SGLT2 inhibitor on lipid profile in patients with type 2 diabetes [J].
Cha, Seon-Ah ;
Park, Yong-Moon ;
Yun, Jae-Seung ;
Lim, Tae-Seok ;
Song, Ki-Ho ;
Yoo, Ki-Dong ;
Ahn, Yu-Bae ;
Ko, Seung-Hyun .
LIPIDS IN HEALTH AND DISEASE, 2017, 16 :1-8
[47]   Better response to the SGLT2 inhibitor dapagliflozin in young adults with type 2 diabetes [J].
Nakamura, Yuta ;
Nagai, Yoshio ;
Terashima, Yuko ;
Nishine, Ami ;
Ishii, Satoshi ;
Kato, Hiroyuki ;
Ohta, Akio ;
Tanaka, Yasushi .
EXPERT OPINION ON PHARMACOTHERAPY, 2015, 16 (17) :2553-2559
[48]   SGLT2 Inhibitors: A Review of Their Antidiabetic and Cardioprotective Effects [J].
Tentolouris, Anastasios ;
Vlachakis, Panayotis ;
Tzeravini, Evangelia ;
Eleftheriadou, Ioanna ;
Tentolouris, Nikolaos .
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2019, 16 (16)
[49]   Liraglutide Versus SGLT-2 Inhibitors in People with Type 2 Diabetes: A Network Meta-Analysis [J].
Lorenzi, Maria ;
Ploug, Uffe Jon ;
Langer, Jakob ;
Skovgaard, Rasmus ;
Zoratti, Michael ;
Jansen, Jeroen .
DIABETES THERAPY, 2017, 8 (01) :85-99
[50]   Are SGLT2 inhibitors joining the mainstream therapy for diabetes type 2? [J].
Hassanabad, Mortaza E. ;
Abad, Zahra F. H. .
DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS, 2019, 13 (03) :1893-1896
12345